ARTICLE | Finance
Big caps under pressure
Buysiders eye gene therapy, SMID-cap catalysts in 2Q19
April 6, 2019 12:06 AM UTC
Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as a boon to SMID-cap companies that buysiders see as takeout targets.
Biogen Inc. has shed $15.5 billion in market cap since announcing on March 21 that it would discontinue a pair of Phase III and a Phase II trial of its anti-amyloid mAb. The company is currently valued at $47.5 billion (see “Biogen’s Lead Balloon”). ...